Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral develops devices for unmet medical needs. Sepsis occurs in 1.7M Americans/year causing 250K deaths, often caused by endotoxin. Our devices measure and remove endotoxin from the bloodstream. An FDA confirmatory trial is underway. Dialco, a Spectral sub, offers SAMI, a novel instrument for renal replacement, cleared by FDA. Dialco is seeking FDA approval for DIMI a unique home dialysis... see more

TSX:EDT - Post Discussion

Spectral Medical Inc > Personalized Medicine...
View:
Post by mercedesman on Feb 07, 2023 10:20am

Personalized Medicine...

“We are entering an era of personalized medicine for critical illnesses,” continued Dr. Kellum. “By breaking up sepsis into subsets that have specific molecular pathogenesis, we believe our strategy targeting endotoxemic septic shock, characterized by high levels of endotoxin in the bloodstream, is far more likely to succeed, where other non-specific therapies have failed time and again. Our goal is to show a large difference in mortality when an anti-endotoxin therapy is applied to carefully selected patients with high endotoxin activity in their bloodstream. Moreover, we have a diagnostic test already in clinical use to identify these patients. We believe this combination of an advanced diagnostic with a specific therapy represents the future of sepsis care.” - JK (KOL)
Comment by oilandgasman on Feb 07, 2023 10:45am
Problem being this chubby Dr can't run a trial to save his life without grad students. 50 and counting..just 100 more to go Scotty McShilling. years to go..not months
Comment by BayStreetWild on Feb 07, 2023 1:29pm
only half a year to go before another financing is needed it seems. Tick tock  
Comment by hmmmmmmmm on Feb 07, 2023 2:02pm
Yeah, management believe they can just bury their head in the sand until they need more money. 21 News Releases and filings in Oct.   10 News Releases and filings in Nov.   Once they got new money in their account..   1 News Release in Dec. to soft announce the loss of control of DIMI/SAMI.   1 News Release in Jan. disclosing the sad enrollment of 1 patient ...more  
Comment by BayStreetWild on Feb 07, 2023 2:36pm
been working for them so far.... salaries keep coming.  
Comment by mercedesman on Feb 07, 2023 2:26pm
You guys should really take things up with the FA80 given their connections to the Board room.  Most of us only have connections to the Bored room. Presumably they would be aware of any Mgt shortcomings,  and YET.... ....they insist on coughing up the cash, whenever it's needed. For $ 11M (less of course the new Baxter quasi-equity contribution) I would have reserved the right to ...more  
Comment by BayStreetWild on Feb 07, 2023 2:33pm
connections to the board room = insider reporting requirements. Who are these FA80 people you keep talking about. Why isn't the OSC requiring whoever this is to file reports on SEDAR?   
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities